December 12, 2024

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of the SyqeAir Metered-Dose Cannabis Inhaler for Chronic Neuropathic Pain: A Phase 1a Study

Syqe®’s first study (2014) examined whether metered and low doses of Δ9-THC allow for dose-dependent pain reduction of chronic neuropathic pain without significant adverse events. Listen to the podcast.

Does Adding CBD to THC-Rich Cannabis Reduce the Side Effects of THC? / Dr. Joshua Aviram

20/03/2023

There are many myths and common beliefs about the THC and CBD ingredients of cannabis among the general public. Are these perceptions backed by clinical studies?

Real World Study Evaluates Medical Cannabis For Cancer Pain Relief

08/06/2022

This study, which was conducted by Dr. Joshua Aviram as part of his postdoctoral fellowship, is the first to assess the possible benefits of medical cannabis for cancer-related pain in oncology patients.

Israeli Microdosing Cannabis Inhaler Receives Approval In Canada

29/04/2021

The real-world data of the trials showed that patients experienced a 90% reduction in adverse effects associated with marijuana use in comparison with other methods such as oil, smoking, and vaping.

Medical Cannabis

SyqeAir Inhaler

Useful Information

Media

Contact Syqe®

Phone. +972-3-376-7338
Email. info@syqemed.com
Syqe® Israel. syqe.co.il

Show Us Some Love

The site and the content therein are provided for general knowledge only and do not constitute advertising and/or medical, pharmacological, or professional advice, diagnosis, treatment, or other healthcare services that in any way generate a doctor-patient relationship and/or recommendation for treatment or products in general, and for medical cannabis products and/or SyqeAir inhaler in particular. You should make all medical or health-related decisions on the basis of professional advice from a licensed physician or qualified healthcare professional who is fully aware of your individual circumstances. For any questions regarding products, including medical cannabis products and/or the SyqeAir inhaler, please consult your attending physician and/or the pharmacist at the dispensing pharmacy. The use and reliance on all content appearing on this site are at your sole responsibility, and Syqe® will not be responsible for any decision or action taken by you as a result of relying on this site.

Day: December 12, 2024

The Pharmacokinetics, Efficacy, Safety, and Ease of Use of the SyqeAir Metered-Dose Cannabis Inhaler for Chronic Neuropathic Pain: A Phase 1a Study

Related Posts

Does Adding CBD to THC-Rich Cannabis Reduce the Side Effects of THC? / Dr. Joshua Aviram

Real World Study Evaluates Medical Cannabis For Cancer Pain Relief

Israeli Microdosing Cannabis Inhaler Receives Approval In Canada